Published in Vaccine Weekly, January 28th, 2009
The challenge was made against elements of a patent filed, and subsequently published in 1994, by Dr. Yvonne Paterson, scientific founder of Advaxis. The patent describes the use of bacteria to deliver an antigen and generate an anti-tumor immune response.
Executive VP of Science and Operations Dr. John Rothman commented, "Following the completion of Advaxis’ Phase I clinical trial in recurrent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-01-28)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.